AEMD

Aethlon Medical, Inc. Common Stock NASDAQ Capital Market
$5.6
Open: $5.5 High: $5.95 Low: $5.21 Close: $5.597
Range: 2021-06-23 - 2021-06-24
Volume: 2,791,881
Market: Open
Powered by Finage Stock APIDelayed data
AEMD
Aethlon Medical, Inc. Common Stock 9635 Granite Ridge Drive San Diego CA, 92123 http://www.aethlonmedical.com
Aethlon Medical Inc is a medical technology company. It operates through two segments namely Aethlon for therapeutic applications and ESI for diagnostic applications.
  • CEO: James A. Joyce
  • Employees: 6
  • Sector: Technology
  • Industry: Computer Hardware
AEMD News
Latest news about the AEMD
  • Aethlon Medical to Release Fourth Quarter Financial Results and Host Conference Call on June 24, 2021

    Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2021, ended March 31, 2021, at 4:15 p.m. ET on Thursday, June 24, 2021.

    View More →
  • Is Aethlon Medical, Inc. (AEMD) A Good Stock To Buy?

    In this article we will check out the progression of hedge fund sentiment towards Aethlon Medical, Inc. (NASDAQ:AEMD) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

    View More →
  • GameStop investor argues why 'there is a fundamental backing to it'

    Heriot-Watt University in Edinburgh, student Thushira Kumarage joins Yahoo Finance's Myles Udland, Julie Hyman and Brian Sozzi to discuss retail trading and meme stocks.

    View More →
  • Aethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    Aethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct offering of 1,380,555 shares of its common stock, at a purchase price per share of $9.00, priced at-the-market under Nasdaq rules.

    View More →
  • Premarket Movers Thursday: Clover Health, FuelCell, GameStop

    Stocks moving in premarket trading Thursday include Clover Health Investments, GameStop, Signet Jewelers, Aethlon Medical and FuelCell Energy.

    View More →
  • Aethlon Medical shares quadruples, ContextLogic and Tilray surge, Wendy’s down amid meme frenzy

    Yahoo Finance’s Emily McCormick reports on the day's trending tickers.

    View More →
  • Aethlon Medical stock more than quadruples on heavy volume

    Shares of Aethlon Medical Inc. skyrocketed more than fourfold on massive volume toward a two-year high in morning trading Wednesday, even though the California-based therapeutic technology company hasn't released any news in nearly a week. On June 3, the company pointed out a "pre-print manuscript" that has not yet completed peer review that was published in "Research Square," highlighting case studies of two critically ill COVID-19 patients who were given access to the company's Hemopurifier th

    View More →
  • Aethlon Quintuples as Hemopurifier Device Gets Reddit Attention

    Shares of Aethlon Medical jumped on Wednesday after the Reddit investing crowd turned its attention to a device from the medical-technology company that showed promising results for two COVID-19 patients. The FDA is currently conducting an early feasibility study of the device.

    View More →
  • AEMD: First Ever In Vivo Removal of COVID Virus From Bloodstream of An Infected Patient

    By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Growing Database Supporting Hemopurifier’s Positive Treatment of COVID-19 Last week Aethlon Medical (NASDAQ:AEMD) announced that the Aethlon Hemopurifier® produced positive results in treating two patients who were critically ill with COVID-19. 1 Neither patient was expected to survive. The Hemopurifier therefore was used under the FDA

    View More →
  • Aethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier®

    Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier®. Both patients were given access to Hemopurifier® treatment through Emergency Use. The manuscript is titled "Removal of COVID-19 Spike Protein, Whole Virus, Exosomes and Exosomal microRNAs by the Hemopurifier® Lectin-Affin

    View More →
  • Aethlon Medical, Inc.'s (NASDAQ:AEMD) Shift From Loss To Profit

    With the business potentially at an important milestone, we thought we'd take a closer look at Aethlon Medical, Inc.'s...

    View More →
  • AEMD: Added Liquidity to Advance Hemopurifier

    By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Aethlon Medical (NASDAQ:AEMD) has implemented measures to enhance its financial flexibility (see below) in order to advance its clinical studies and move the Hemopurifier towards potential regulatory approval and commercialization. The company has two clinical studies of the Hemopurifier underway. One study is of patients with head and

    View More →
  • Aethlon Medical to Participate in Two Upcoming Healthcare Investor Conferences

    Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that the company will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021, and the Maxim Group and M Vest 2021 Emerging Growth Virtual Conference on March 17-18, 2021.

    View More →
  • AEMD: Company Provides Update on Studies and Business Outlook

    By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Aethlon Medical, Inc. (NASDAQ:AEMD) reported 3Q FY2021 results last night and provided an updated outlook on the two clinical studies underway. The company is developing products to diagnose and treat diseases in oncology and viral diseases that are life and organ threatening and not addressed with already approved treatments, is setting

    View More →
  • Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 10, 2021 / Aethlon Medical, Inc. (NASDAQ:AEMD) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 10, 2021 at 4:30 PM Eastern Time.

    View More →
  • Aethlon Medical (NASDAQ:AEMD) Is In A Good Position To Deliver On Growth Plans

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

    View More →
  • Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 10, 2021

    Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its third quarter fiscal year 2021, ended December 31, 2020, at 4:15 p.m. EST on Wednesday, February 10, 2021.

    View More →
  • AEMD: Establishing The Infrastructure To Support Expanding Opportunities

    By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Management team with vast healthcare experience Aethlon Medical Inc. (NASDAQ:AEMD), a medical technology company engaged in developing products to diagnose and treat diseases in oncology and viral diseases that are life and organ threatening and not addressed with already approved treatments, is setting up internal infrastructure to

    View More →
  • Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer

    Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Guy Cipriani as Senior Vice President and Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer. In his new role, Mr. Cipriani will oversee business development and partnerships, while also contributing to fundraising and corporate development. Dr. LaRosa will be responsible for the clinical development of Aethlon's Hemopurifier®, including leading clinical operations and regulatory strategy.

    View More →
  • Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference

    Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held Jan. 11-14, 2021.

    View More →